GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...

Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).